Kymera Therapeutics' (KYMR) "Buy" Rating Reiterated at Truist Financial
Truist Financial restated a “buy” rating and set a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday.
Source link